SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

VOCERYQ

INO·INOVIO PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Why 4/10
VOCERYQ received FDA accelerated approval on October 30, 2026, resolving the defining binary catalyst. As an approved, marketed drug with no pending regulatory decision (PDUFA or pivotal readout), the next catalysts are commercial execution and a confirmatory study protocol, which are not hard binary events. ImpactScore is therefore 4 per the rubric.
Actionable Insight NEUTRAL

With the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

Price Chart

Loading chart...

Executive Summary

VOCERYQ (INO-3107) is Inovio Pharmaceuticals' first FDA-approved product, granted accelerated approval on October 30, 2026 for recurrent respiratory papillomatosis (RRP), a rare HPV-caused airway disease that typically requires repeated surgeries. It is the first plasmid DNA-based immunotherapy ever approved in the U.S., targeting HPV types 6 and 11. The approval was based on a 32-patient Phase 1/2 open-label study in which 27% of evaluable patients required no surgical intervention for 12 months. Inovio faces a narrow commercial window: cash runway extends only into late Q1 2027, it must compete with Precigen's already-marketed Papzimeos, and continued approval depends on a confirmatory study. The stock surged ~270% pre-market on the news, reflecting the platform validation but also raising questions about whether commercial upside is already priced in.

How It Works

VOCERYQ is a DNA-based immunotherapy (a plasmid, a small circle of DNA) that is injected into muscle and delivered with a brief electrical pulse (electroporation) to help cells absorb it. Once inside cells, the DNA instructs them to produce proteins from HPV types 6 and 11, the viruses that cause RRP. This trains the immune system's T cells to recognize and attack HPV-infected cells in the airway, reducing the growths that require repeated surgery.

Trial Status

Approval was based on the completed Phase 1/2 RRP-001 study (NCT04398433), an open-label trial of 32 adults with RRP who had at least two surgeries in the prior year. Of 26 efficacy-evaluable patients (with >=3 prior surgeries), 27% (7/26) required no surgical excision for 12 months post-treatment, and 72% saw a 50-100% reduction in surgeries in Year 1. Long-term follow-up data through Year 2 showed sustained reduction in surgical burden. A confirmatory post-approval study is required, with a draft protocol due to the FDA by end of 2026 and final alignment by mid-2027.

The Two-Sided Case

▲ Bull Case5
VOCERYQ is the first FDA-approved DNA medicine in U.S. history, validating Inovio's plasmid DNA platform and opening a potential pipeline value for other candidates.
It targets a U.S. prevalent population of at least 25,000 RRP patients who previously had no non-surgical option until Papzimeos in 2025; a second therapy expands the market and gives physicians a differentiated mechanism (DNA vs. adenoviral).
Analyst consensus is bullish: 5 of 7 analysts rate Buy or Strong Buy, with a mean price target of $3.17 (vs. ~$2.23 pre-market), and HC Wainwright upgraded from Neutral to Buy on Nov 2.
72% of patients in the Phase 1/2 trial saw a 50-100% reduction in surgeries in the first year, and long-term follow-up showed sustained benefit through Year 2, supporting durable disease control.
Inovio has a focused commercial strategy via Syneos Health targeting ~400 U.S. laryngologists, a concentrated prescriber base that could enable efficient market penetration.
▼ Bear Case5
Accelerated approval rests on a single-arm, open-label Phase 1/2 study of just 32 patients; only 27% (7/26) of evaluable patients achieved the complete response of no surgery for 12 months, a modest efficacy signal.
Continued approval is contingent on a confirmatory study. Inovio must submit a draft protocol by end of 2026 and finalize by mid-2027; failure to verify clinical benefit could lead to withdrawal.
Inovio faces entrenched competition from Precigen's Papzimeos, approved in August 2025 as the first RRP therapy, which already generated $74.7M in sales and has a head start in the laryngologist prescriber base.
Cash runway extends only into late Q1 2027, per the Q2 2026 report, meaning the company must fund a commercial launch and confirmatory study simultaneously with no product revenue history and an ~$80M market cap.
The stock surged ~270% pre-market on the approval news, potentially pricing in much of the commercial upside before any revenue materializes.

Upcoming Catalysts

  • Confirmatory study draft protocol submission to FDA (due end of 2026)
  • Confirmatory study final protocol alignment with FDA (expected mid-2027)
  • Initial commercial availability and ordering (within ~60 days from Oct 30, 2026)
  • Full commercial launch and field deployment (Q1 2027)
  • Q3 2026 earnings report (scheduled Nov 9, 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

INOVIO PHARMACEUTICALS, INC. 8-K INO ·Originating report

Sources · 12

Hover a chip for the title
1 ir.inovio.com2 fda.gov3 drugs.com4 trialfriend.com5 clinicaltrials.gov6 sec.gov7 ainvest.com8 ainvest.com9 prnewswire.com10 hcplive.com11 biospace.com12 regulatorynews.com